Shire’s Ornskov Says Baxalta Integration on Track, Ups Synergies Forecast

Shire PLC was "firing on all cylinders" in the second-quarter, according to its CEO Flemming Ornskov, while simultaneously absorbing rare disease specialist Baxalta, and now expects annual synergies from the deal of more than $700m in three years, up from the $500m forecast ahead of the acquisition's closing in June.